



# SAFETY DATA SHEET

Revision date: 09-Jan-2018

Version: 3.1

Page 1 of 9

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Celontin (Methsuximide) Capsules 150 and 300 mg

**Trade Name:** CELONTIN; PETINUTIN

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as anticonvulsant

### Details of the Supplier of the Safety Data Sheet

Pfizer Inc  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ltd  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
**CHEMTREC (24 hours): 1-800-424-9300**  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours): +1-703-527-3887**

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Acute Oral Toxicity: Category 4  
Reproductive Toxicity: Category 2

### Label Elements

**Signal Word:** Warning  
**Hazard Statements:** H302 - Harmful if swallowed  
H361d - Suspected of damaging the unborn child

**Precautionary Statements:** P202 - Do not handle until all safety precautions have been read and understood  
P264 - Wash hands thoroughly after handling  
P270 - Do not eat, drink or smoke when using this product  
P281 - Use personal protective equipment as required  
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell  
P330 - Rinse mouth  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and 300 mg  
Revision date: 09-Jan-2018

Page 2 of 9

Version: 3.1



### Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	*
Starch	9005-25-8	232-679-6	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	*
Methsuximide	77-41-8	201-026-7	Acute Tox.4 (H302) Repr.2 (H361d)	80

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	*
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	*

#### Additional Information:

\* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

##### Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

##### Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

##### Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and  
300 mg  
Revision date: 09-Jan-2018

Page 3 of 9

Version: 3.1

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.  
**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and  
300 mg  
Revision date: 09-Jan-2018

Page 4 of 9

Version: 3.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m<sup>3</sup>

#### Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	4.0 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Switzerland OEL -TWAs	3 mg/m <sup>3</sup>

#### Colloidal silicon dioxide

Australia TWA	2 mg/m <sup>3</sup>
Austria OEL - MAKs	4 mg/m <sup>3</sup>
Czech Republic OEL - TWA	0.1 mg/m <sup>3</sup>
	4.0 mg/m <sup>3</sup>
Estonia OEL - TWA	2 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	4 mg/m <sup>3</sup>
Germany (DFG) - MAK	4 mg/m <sup>3</sup>
Ireland OEL - TWAs	6 mg/m <sup>3</sup>
	2.4 mg/m <sup>3</sup>
Latvia OEL - TWA	1 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m <sup>3</sup>
Slovenia OEL - TWA	0.3 mg/m <sup>3</sup>
Switzerland OEL -TWAs	4 mg/m <sup>3</sup>

#### Methsuximide

Pfizer OEL TWA-8 Hr: 700µg/m<sup>3</sup>

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and 300 mg  
Revision date: 09-Jan-2018

Page 5 of 9

Version: 3.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>Hands:</b>	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
<b>Eyes:</b>	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
<b>Skin:</b>	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
<b>Respiratory protection:</b>	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Capsule	<b>Color:</b>	Light yellow
<b>Odor:</b>	Odorless	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

<b>Solvent Solubility:</b>	No data available
<b>Water Solubility:</b>	No data available
<b>pH:</b>	No data available.
<b>Melting/Freezing Point (°C):</b>	No data available
<b>Boiling Point (°C):</b>	No data available.

**Partition Coefficient: (Method, pH, Endpoint, Value)**

#### Gelatin

No data available

#### D & C yellow No. 10

No data available

#### Colloidal silicon dioxide

No data available

#### Sodium lauryl sulfate

No data available

#### FD&C yellow No.6 aluminum lake

No data available

#### Starch

No data available

#### Methsuximide

No data available

**Decomposition Temperature (°C):** No data available.

<b>Evaporation Rate (Gram/s):</b>	No data available
<b>Vapor Pressure (kPa):</b>	No data available
<b>Vapor Density (g/ml):</b>	No data available
<b>Relative Density:</b>	No data available
<b>Viscosity:</b>	No data available

#### Flammability:

<b>Autoignition Temperature (Solid) (°C):</b>	No data available
<b>Flammability (Solids):</b>	No data available
<b>Flash Point (Liquid) (°C):</b>	No data available
<b>Upper Explosive Limits (Liquid) (% by Vol.):</b>	No data available

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and  
300 mg  
Revision date: 09-Jan-2018

Page 6 of 9

Version: 3.1

Lower Explosive Limits (Liquid) (% by Vol.): No data available  
Polymerization: Will not occur .

### 10. STABILITY AND REACTIVITY

Reactivity: No data available  
Chemical Stability: Stable under normal conditions of use.  
Possibility of Hazardous Reactions  
Oxidizing Properties: No data available  
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.  
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers  
Hazardous Decomposition Products: No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.  
**Short Term:** Antiepileptic drug: may cause nervous system effects  
**Long Term:** Animal studies have shown a potential to cause adverse effects on the fetus.  
**Known Clinical Effects:** The most common adverse effects seen with the therapeutic use of this drug are nausea or vomiting, constipation, weight loss, and epigastric or abdominal pain. Other less common effects include CNS depression (headache, drowsiness, dizziness, incoordination, and blurred vision), behavioral changes, hematological effects (eosinophilia, leukopenia, monocytosis, and pancytopenia with or without bone-marrow depression), and skin reactions (urticaria and Stevens-Johnson syndrome) have also been reported. Psychosis, suicidal behavior, and auditory hallucinations have been reported rarely.

#### Acute Toxicity: (Species, Route, End Point, Dose)

**D & C yellow No. 10**  
Rat Oral LD50 2000 mg/kg

**Sodium lauryl sulfate**  
Rat Oral LD50 1288 mg/kg

**Methsuximide**  
Mouse Oral LD50 900-1405 mg/kg  
Rat Oral LD50 960mg/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

**Sodium lauryl sulfate**  
Eye Irritation Rabbit Moderate  
Skin Irritation Rabbit Mild Moderate  
Skin Sensitization - GPMT Guinea Pig Negative  
Skin Sensitization - LLNA Mouse Negative

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Methsuximide**  
28 Day(s) Mouse Oral 232 mg/kg/day LOAEL weight gain

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and 300 mg  
Revision date: 09-Jan-2018

Page 7 of 9

Version: 3.1

### 11. TOXICOLOGICAL INFORMATION

26 Week(s) Rat Oral 281 mg/kg/day NOEL None identified

#### **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

##### **Methsuximide**

Embryo / Fetal Development Mouse No route specified Dose not specified Teratogenic

#### **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

##### **Sodium lauryl sulfate**

Bacterial Mutagenicity (Ames) *Salmonella* Negative

**Carcinogen Status:** See below

##### **Colloidal silicon dioxide**

**IARC:** Group 3 (Not Classifiable)  
**NTP:** Reasonably Anticipated To Be A Human Carcinogen

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

#### **Toxicity:**

##### **Aquatic Toxicity: (Species, Method, End Point, Duration, Result)**

##### **Sodium lauryl sulfate**

*Oncorhynchus mykiss* (Rainbow Trout) LC50 96 Hours 3.6 mg/L

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

#### **Waste Treatment Methods:**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and  
300 mg  
Revision date: 09-Jan-2018

Page 8 of 9

Version: 3.1

---

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

#### Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

##### D & C yellow No. 10

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

##### Sodium lauryl sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1

##### Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

##### Gelatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6

##### FD&C yellow No.6 aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present



## SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and  
300 mg  
Revision date: 09-Jan-2018

Page 9 of 9

Version: 3.1

### 15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1

#### Colloidal silicon dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

#### Methsuximide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-026-7

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

**Data Sources:** Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information. Updated Section 8 - Exposure Controls / Personal Protection.

**Revision date:** 09-Jan-2018

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**